Journal
PEDIATRIC BLOOD & CANCER
Volume 61, Issue 8, Pages 1486-1489Publisher
WILEY-BLACKWELL
DOI: 10.1002/pbc.24989
Keywords
developmental therapeutics; mTOR inhibitor; preclinical testing
Categories
Funding
- National Cancer Institute [NO1-CM-42216, NO1-CM91001-03, CA21765, CA108786]
Ask authors/readers for more resources
MLN0128 is an investigational small molecule ATP-competitive inhibitor of the serine/threonine kinase mTOR. MLN0128 was tested against the in vitro panel at concentrations ranging from 0.1nM to 1M and against the PPTP in vivo panels at a dose of 1mg/kg administered orally dailyx28. In vitro the median relative IC50 concentration was 19nM. In vivo MLN0128 induced significant differences in EFS in 24/31 (77%) solid tumor models, but 0/7 ALL xenografts. The modest activity observed for MLN0128 against the PPTP preclinical models is similar to that previously reported for another TOR kinase inhibitor. Pediatr Blood Cancer 2014; 61:1486-1489. (c) 2014 Wiley Periodicals, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available